Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 2.
Purpose: to study long-term results of anti-VEGF therapy for macular diseases of patients followed up for 60 months in real clinical practice. Materials and methods. The research group included 57 patients (43 women, 14 men; median age 62 years) who received antiVEGF therapy (ranibizumab, aflibercep...
Saved in:
Main Authors: | E. V. Bobykin, R. V. Buslaev, V. Y. Krokhalev, O. V. Morozova, N. S. Beresneva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Real Time Ltd
2022-12-01
|
Series: | Российский офтальмологический журнал |
Subjects: | |
Online Access: | https://roj.igb.ru/jour/article/view/1091 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 1
by: E. V. Bobykin, et al.
Published: (2022-09-01) -
The impact of switching from anti-VEGF therapy to dexamethasone intravitreal implant on refractory macular edema in patients with retinal vein occlusion: A systematic review and meta-analysis
by: He-Ping Zhang, et al.
Published: (2025-08-01) -
Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice
by: E. Yu. Santoro
Published: (2018-12-01) -
Factors determining the compliance of patients receiving anti-VEGF therapy for macular diseases with long-term follow-up in real-life practice
by: E. V. Bobykin, et al.
Published: (2021-03-01) -
Åfficacy of nutraceutical drug in the intermediate and wet forms of age-related macular degeneration
by: E. N. Eskina, et al.
Published: (2023-07-01)